BERLIN, March 27, 2008 (PRIME NEWSWIRE) -- Jerini AG (FSE:JI4) announced today its financial results for the fiscal year ended December 31, 2007. “We have made significant progress in moving both the European and US regulatory processes forward and are expecting the EMEA and FDA decisions for Icatibant in the treatment of hereditary angiodema (HAE) at the end of next month,” said Jens Schneider-Mergener, CEO of Jerini. “Given the positive feedback from physicians who have treated patients with Icatibant, I look forward to the day when we can bring this novel medication to HAE patients.”
